66 results
424B3
ZVRA
Zevra Therapeutics Inc
10 Apr 24
Prospectus supplement
4:23pm
materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may
424B5
ZVRA
Zevra Therapeutics Inc
21 Nov 23
Prospectus supplement for primary offering
7:40pm
projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time
8-K
EX-99.2
7q1 hs8nqd
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-10.1
fktpoi5dnbu1pdi01ka
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
424B3
mz702 52c1
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
qoiu9 3u9ct7bs
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
2lms 8ngzr
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
jjhf9v6yqx 0u
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-2.1
o46sq c48ns4y
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-99.1
q6u phvftl8xu8d9x9c
30 Mar 22
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
4:36pm
424B3
9cfhgccx0eqsfzxv8in
10 Nov 21
Prospectus supplement
5:19pm
424B3
ylb0s202
16 Aug 21
Prospectus supplement
12:00am
424B3
oxzeh exos4lzad
12 Jul 21
Prospectus supplement
4:18pm